RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative…
Category: Business
Transcend Vivoscope to Offer Turnkey Miniature Two-photon Imaging Systems with poLight ASA Tunable Optics
HORTEN, Norway–(BUSINESS WIRE)– #Alzheimers–Transcend Vivoscope will debut the SUPERNOVA-600 mini2P, incorporating poLight ASA TLens® tunable optics, at the #SfN’24 event Oct. 5-9 in Chicago, IL
Marshall B. Ketchum University Hosts Second Annual Alumni Homecoming and Distinguished Alumni Awards
FULLERTON, Calif.–(BUSINESS WIRE)– #AlumniAwards–Marshall B. Ketchum University (MBKU) recently recognized the remarkable accomplishments of its alumni during the 2024 Distinguished Alumni Awards Ceremony during its second annual homecoming event. T…
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the res…
Harrow Relaunches TRIESENCE®
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic co…
Novaliq和Laboratoires Théa宣布建立合作伙伴关系并获得Vevizye®(环孢菌素0.1%滴眼液)欧盟批准
德国海德堡、马萨诸塞州坎布里奇和法国克莱蒙特-费朗–(BUSINESS WIRE)–(美国商业资讯)– 以独特的EyeSol®无水技术为基础、专注开发一流眼科治疗药物的生物制药公司Novaliq与欧洲领先的独立眼科护理集团Laboratoires Théa (Théa) 宣布，Vevizye®（环孢素0.1%滴眼液）获得欧盟委员会批准，并且双方已签订合作伙伴关系协议，Théa获得该产品在欧洲及中东和北非（MENA）部分国家的商业化权利。 Vevizye®以Novaliq的专利EyeSol®技术…
Samenvatting: Novaliq en Laboratoires Théa kondigen een partnerschap en EU-goedkeuring aan voor Vevizye® (oogdruppels met 0,1% ciclosporine)
HEIDELBERG, Duitsland & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Frankrijk–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich toespitst op oogtherapeutica van topkwaliteit op basis van de unieke, watervrije EyeSol®-technologie, en Laboratoire…
Riassunto: Novaliq e Laboratoires Théa annunciano la sigla di una partnership e l’approvazione da parte della UE di Vevizye® (soluzione in collirio liquido allo 0,1% di ciclosporin)
HEIDELBERG, Germania & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Francia–(BUSINESS WIRE)–Novaliq, una società biofarmaceutica il cui focus è sullo sviluppo di terapie oculari all’avanguardia basate sull’esclusiva tecnologia EyeSol® per prodotti privi di a…
Novaliq et les laboratoires Théa annoncent un partenariat et l'approbation par l'UE de Vevizye® (solution de collyre à 0,1 % de ciclosporine)
HEIDELBERG, Allemagne & CAMBRIDGE, Mass. & CLERMONT-FERRAND, France–(BUSINESS WIRE)–Novaliq, société biopharmaceutique spécialisée dans les traitements oculaires de première et de meilleure qualité basés sur la technologie unique sans eau EyeSol®, et…
Novaliq und Laboratoires Théa verkünden Partnerschaft und EU-Zulassung für Vevizye® (0,1%ige Ciclosporin-Augentropfenlösung)
HEIDELBERG, Deutschland & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Frankreich–(BUSINESS WIRE)–Novaliq, ein biopharmazeutisches Unternehmen, das sich auf erste und beste Augentherapeutika konzentriert, die auf der einzigartigen wasserfreien EyeSol®-Techno…
Resumen: Novaliq y Laboratoires Théa anuncian su asociación y la aprobación en la UE de Vevizye® (ciclosporina 0,1 % solución colirio)
HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts y CLERMONT-FERRAND, Francia–(BUSINESS WIRE)–Novaliq, una compañía biofarmacéutica centrada en la primera y mejor terapia ocular de su clase basada en la exclusiva tecnología EyeSol® sin agua, y Laborato…
Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)
HEIDELBERG, Germany & CAMBRIDGE, Mass. & CLERMONT-FERRAND, France–(BUSINESS WIRE)– #CHMP–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, and Laboratoire…
NextGen Healthcare Introduces AI-Driven Ambient Listening Innovation for Ophthalmologists and Optometrists
REMOTE-FIRST COMPANY/CHICAGO–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare today announced that its AI-driven ambient listening solution NextGen® Ambient Assist is now available to ophthalmologists and optometrists. NextGen Ambient Assist s…
The Canadian Association of Optometrists (CAO) Raises Awareness About the Myopia Epidemic Among Children and the Importance of Limiting Screen Time
OTTAWA, Ontario–(BUSINESS WIRE)–As October marks Children Vision Month, the Canadian Association of Optometrists (CAO) releases a new national campaign to raise awareness about myopia, and to enlighten parents and caregivers about the crucial signifi…
L'Association canadienne des optométristes (ACO) sensibilise à l'épidémie de myopie chez les enfants et à l'importance de limiter le temps devant un écran
OTTAWA, Ontario–(BUSINESS WIRE)–Octobre étant le mois de la santé visuelle des enfants, l’Association canadienne des optométristes (ACO) lance une nouvelle campagne nationale sur la myopie et pour sensibiliser les parents, tuteurs et tutrices à l’imp…
Dopavision Presented Key Data From Its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference
BERLIN–(BUSINESS WIRE)–Dopavision presented the primary 6-month clinical data from its proof-of-concept study of MyopiaX, a transformative approach that aims to control juvenile-onset myopia, on Friday, September 27th, 2024 at the 19th International …
GenSight Biologics publie ses résultats financiers du premier semestre 2024 et un point sur ses activités
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladie…
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Ophthalmic Lens and Precision Optics Manufacturing Machines Global Strategic Business Report to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lens and Precision Optics Manufacturing Machines – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Ophthalmic Lens and Precision Optics Manufac…
Seeing a Clearer Path to Eye Health Equity: 20/20 Onsite Mobile Vision Clinic to Conduct Free Eye Screenings at the American Diabetes Association® DMV Step Out: Walk to Stop Diabetes® on 9/21/24
WASHINGTON–(BUSINESS WIRE)–20/20 Onsite Mobile Vision Clinic to Conduct Free Eye Screenings at the American Diabetes Association® DMV Step Out: Walk to Stop Diabetes®